Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 9,649 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Clear all
Not listed Not applicable Interventional

Improving Life Chances of Disadvantaged Youth: Testing Best-Practice Academic vs. Non-Academic Supports

NCT01927523
View directory record Official record
Conditions
Youth Violence, Crime, Educational Achievement
Interventions
BAM, Match
Behavioral · Other
Lead sponsor
University of Chicago
Other
Eligibility
Male only
Enrollment
5,344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 25, 2026, 5:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Seasonal Patterns of Stress, Diet and Physical Activity - Life in All Seasons (LENAS)

NCT01674296
View directory record Official record
Conditions
Obesity, Stress, Feeding Behavior, Physical Activity
Interventions
Not listed
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
40 Years to 60 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

NCT03187262
View directory record Official record
Conditions
Waldenström Macroglobulinemia
Interventions
Daratumumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of Oral TP-1454

NCT04328740
View directory record Official record
Conditions
Advanced Solid Tumor, Anal Cancer
Interventions
TP-1454 monotherapy
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

NCT00432510
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
San Diego, California • Walnut Creek, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 25, 2026, 5:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PKU Skin Stripping

NCT04368624
View directory record Official record
Conditions
Phenylketonurias
Interventions
Skin Tape, Blood Draw
Other · Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages

NCT04971317
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Dental Caries
Interventions
Sugar-Sweetened Beverage (SSB) Video, Water Video, Control
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 12 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 25, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

NCT00971191
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
PF-00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia

NCT03583697
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Up to 59 Months
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 2 Interventional

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

NCT04965597
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
Interventions
Treosulfan, Fludarabine Phosphate, Tacrolimus, Methotrexate, Lapine T-Lymphocyte Immune Globulin, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Quality-of-Life Assessment, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, X-Ray Imaging, Computed Tomography
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 49 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

ADAPT Study: Assessing Diet, Appetite and Physiology Throughout Weight Loss Study)

NCT06174389
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Weight Loss Program
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 25, 2026, 5:18 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

NCT00962260
View directory record Official record
Conditions
Gaucher Disease
Interventions
Plant cell expressed recombinant glucocerebrosidase (prGCD)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
U.S. locations
14
States / cities
La Jolla, California • Aurora, Colorado • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 25, 2026, 5:18 AM EDT
Not listed Phase 2 Interventional

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

NCT04840459
View directory record Official record
Conditions
Covid19
Interventions
BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
Biological
Lead sponsor
Sohail Rao
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Edinburg, Texas • Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 25, 2026, 5:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans

NCT05120635
View directory record Official record
Conditions
Fear, GAD, Emotional Memory, PTSD
Interventions
Deep Brain Stimulation, Virtual and augmented reality tasks
Device · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 2 Interventional

HORMA: Hormonal Regulators of Muscle and Metabolism in Aging

NCT00183040
View directory record Official record
Conditions
Sarcopenia, Muscle Weakness, Frailty
Interventions
Topical testosterone, Recombinant human growth hormone
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years to 90 Years · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Oct 25, 2026, 5:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

NCT06028074
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
GIM122
Drug
Lead sponsor
Georgiamune Inc
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Enrolling by invitation Phase 2 Interventional

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

NCT05957913
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Truvada (tenofovir/emtricitabine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Active, not recruiting Not applicable Interventional Results available

Early Protein Supplementation in Extremely Preterm Infants Fed Human Milk

NCT04325308
View directory record Official record
Conditions
Prematurity; Extreme, Feeding Disorder Neonatal, Breast Milk Expression, Growth Failure, Microbial Colonization
Interventions
Protein-enriched human milk diet, Usual human milk diet
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 4 Days
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

NCT06068868
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
ABBV-787
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Duarte, California • Sacramento, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 25, 2026, 5:18 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions
Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
304
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 227 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Recruiting Phase 1 Interventional

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

NCT05865535
View directory record Official record
Conditions
Cachexia
Interventions
AV-380
Biological
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Beverly Hills, California • Lakewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 25, 2026, 5:18 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

NCT00500240
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Insulin Glargine, Insulin Aspart
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 25, 2026, 5:18 AM EDT
Completed No phase listed Observational

Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer

NCT00897468
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, medical chart review
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 25, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

NCT00367991
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Recombinant human erythropoietin alfa (drug), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 25, 2026, 5:18 AM EDT